Stock, pipeline and biotech catalyst intelligence
Market expectations
Street view at a glance
The average target implies 11.3% downsideTargets are estimates—not guarantees—and can change after company updates.Wall Street consensus
UnderperformBased on 2 analyst opinionsPrice-target range
$12.50Company profile
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.